Rosen Comments on Korean Pharma Companies Doing Business in the U.S.
April 18, 2019
Korea Biomedical Review
Partner David Rosen was quoted in a Korea Biomedical Review article, “How Korean pharma companies can succeed in US,” about how Korean pharmaceutical and biosimilar companies can find success in America.
Rosen, speaking at BIO KOREA 2019, said it is essential for Korean companies to develop drugs with a sense of responsibility for making the products safe. He also said if such expectations are not met, the companies can receive sanctions and penalties, including regulatory enforcement action, civil monetary penalties, and criminal liability.
“Import detention is something that everyone should be afraid the most as the Food and Drug Administration can block any import of the product,” he said. “Therefore, companies have to respond to all warning letters and the concerns that the FDA has, and address them.”
Rosen, speaking at BIO KOREA 2019, said it is essential for Korean companies to develop drugs with a sense of responsibility for making the products safe. He also said if such expectations are not met, the companies can receive sanctions and penalties, including regulatory enforcement action, civil monetary penalties, and criminal liability.
“Import detention is something that everyone should be afraid the most as the Food and Drug Administration can block any import of the product,” he said. “Therefore, companies have to respond to all warning letters and the concerns that the FDA has, and address them.”
People
Related News
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."
July 24, 2025
In the News
Gregory Husisian and David Simon on Tariff Evasion – 'Huge money at stake'
Foley & Lardner LLP partners Gregory Husisian and David Simon detailed the rise and risks of tariff evasion in the POLITICO article, "As Trump raises tariffs, companies find ways to cheat — and risk getting caught."
July 23, 2025
In the News
Aaron Maguregui on AI Scribes in Health Care – 'Technically, it's a third party listening'
Foley & Lardner LLP partner Aaron Maguregui shared insights on the growing applications for artificial intelligence across health care in the healthleaders article, “Is Your AI Scribe HIPAA-Compliant?“